Fox Chase Cancer Center | Strategic Alliance Partners

April 29, 2015

Although patients with invasive lobular carcinoma are typically treated with the same therapeutic strategies as those with infiltrating ductal malignancies, ILC is emerging as a molecularly complex and distinct tumor type that suggests different approaches may be effective.

February 05, 2015

Jennifer Yuchen Shih, MD, a medical oncologist at Fox Chase Cancer Center, discusses the ABCSG-8 and BIG 1-98 studies and their impacts on the treatment of lobular breast cancer compared to ductal breast cancers.

February 04, 2015

Lori Goldstein, MD, the director of the Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center, discusses a neoadjuvant trial of lapatinib and trastuzumab with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer.

January 07, 2015

Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.

August 28, 2014

Although advances in endocrine therapy for women with estrogen receptor (ER)-positive breast cancer have been made in recent years, de novo and acquired resistance to treatments remain important clinical problems, and efforts to identify effective modalities to overcome this challenge continue.

July 16, 2014

Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses a study presented at the 2014 ASCO Annual Meeting where researchers profiled more than 1900 sarcoma specimens to try to identify potential novel treatment modalities for patients with this disease.

March 11, 2014

Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial that looked at overcoming mTOR resistance with an HDAC inhibitor in renal cell carcinoma (RCC).

January 03, 2014

Antiangiogenic agents hold promise in gynecologic cancers, as evidenced by their single-agent activity in malignancies including ovarian cancer, recurrent endometrial cancer, and cervical cancer.

November 01, 2013

Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women's Cancer Center, Fox Chase Cancer Center, discusses the toxicity profile of bevacizumab when used to treat patients with ovarian cancer.

October 25, 2013

At the recent NCCN 8th Annual Congress on Hematologic Malignancies, Michael Millenson, MD, Fox Chase Cancer Center, discussed considerations in selecting second- and third-generation tyrosine-kinase inhibitors for the management of chronic myelogenous leukemia

October 09, 2013

Robert A. Burger, MD, FACOG, FACS, Professor, Department of Surgical Oncology, Director, Women's Cancer Center, Fox Chase Cancer Center, discusses the use of bevacizumab in patients with ovarian cancer.

December 05, 2011

Dr. Ranee Mehra from Fox Chase Cancer Center Discusses DNA Repair Enzymes

October 28, 2011

Dr. Lori Goldstein from Fox Chase Cancer Center on the Fox Chase Breast Evaluation Center

October 26, 2011

Dr. Lori Goldstein from Fox Chase Cancer Center on Fulvestrant in Metastatic Breast Cancer

September 28, 2011

Dr. Barbara Burtness from Fox Chase Cancer Center on the Head and Neck Symposium Design

September 27, 2011

Dr. Barbara Burtness from Fox Chase Cancer Center Discusses the Upcoming Head and Neck Cancer Symposium